NEWBIO THERAPEUTICS INC has a total of 23 patent applications. Its first patent ever was published in 2014. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are LYTIX BIOPHARMA AS, Pierre Fabre Médicament and TEVA PHARMACEUTICALS INT GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Canada | 3 | |
#4 | United States | 3 | |
#5 | Australia | 2 | |
#6 | China | 2 | |
#7 | Republic of Korea | 2 | |
#8 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Heterocyclic compounds | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Han Nianhe | 23 |
#2 | An Deqiang | 23 |
#3 | Yang Chun | 23 |
#4 | Zeng Di | 18 |
#5 | Zhu Peng | 16 |
#6 | Jian Li | 14 |
#7 | Yang Hang | 14 |
#8 | Wang Baoxiang | 10 |
#9 | Li Huali | 8 |
#10 | Li Mingzhen | 6 |
Publication | Filing date | Title |
---|---|---|
WO2020088587A1 | Anti-CD79b Antibodies, Drug Conjugates, and Applications thereof | |
WO2019011078A1 | Oxadiazole linkers and use thereof | |
AU2018317230A1 | Tetramaleimide linkers and use thereof | |
CN106267225A | Three maleimide amine type connexon and application thereof | |
CN106279352A | The derivant of aplysiatoxin 10 and application thereof | |
AU2014210301A1 | Tridentate connexon and use thereof |